Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
A recent study of California women with early-stage breast cancer showed that bilateral mastectomy has the same impact on survival as breast-conserving surgery, or lumpectomy, followed by radiation therapy.
After evaluating long-term results from recent studies, the American Society of Clinical Oncology, ASCO, issued a guideline update for tamoxifen therapy for hormone receptor-positive breast cancer.
The update advises doctors to offer up to 10 years of tamoxifen treatment, instead of the previous standard 5-year duration
LBBC highlights results of a phase III clinical trial studying a medicine used to protect premenopausal women’s ovaries during chemotherapy. Findings were announced during the American Society of Clinical Oncology 2014 Breast Cancer Symposium on September 4.
Researchers with the phase II GeparSixto trial found that women with triple-negative breast cancer were significantly more likely to achieve pathological complete response, or pCR, when carboplatin was added to their course of other anti-cancer medicines. For this study, pCR was defined as the absence of cancer after treatment given before surgery.
A recent study published in The New England Journal of Medicine looked at harmful mutations, or changes in the DNA of a cell, found on the PALB2 gene. The study found that, like BRCA1 and BRCA2 gene mutations, PALB2 mutations greatly increase a person’s chance of getting breast cancer.
LBBC highlights a study reported on the first day of the American Society of Clinical Oncology 2014 Breast Cancer Symposium: an analysis of breast cancer recurrence rates after pre-surgery, or neoadjuvant, chemotherapy.
Although more women are having lumpectomies, an evaluation of data in the National Cancer Database found socioeconomic barriers prevent some from choosing this surgery. Meeghan Ann Lautner, MD, of the University of Texas San Antonio, announced findings at the American Society of Clinical Oncology 2014 Breast Cancer Symposium on September 4.
Everolimus May Help Those With HER2-positive Breast Cancer That No Longer Responds Well to TrastuzumabSeptember 9, 2014
Adding everolimus could make trastuzumab work better in women who aren’t seeing the same benefits this medicine once gave them. But everolimus isn’t without risk – it has the potential to lower the user’s quality of life.
A panel of experts reviewed key points and limitations of a new national guideline on margins for lumpectomy, also called breast-conserving surgery, at the American Society of Clinical Oncology 2014 Breast Cancer Symposium in San Francisco yesterday. They also discussed how it can be used in clinical practice.
Findings about the influence of PALB2 gene mutations on the risk of getting breast cancer could influence genetic testing. They could also affect the way people with a mutation on this gene make treatment decisions in the future.